Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 16.4% from the November 30th total of 49,500 shares. Based on an average daily volume of 170,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.9% of the company’s shares are sold short.

Analyst Ratings Changes

ADIL has been the topic of several analyst reports. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on Adial Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $8.00 price objective on the stock.

Adial Pharmaceuticals Trading Down 1.9 %

NASDAQ:ADIL opened at $1.01 on Wednesday. The business’s 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.05. Adial Pharmaceuticals has a fifty-two week low of $0.77 and a fifty-two week high of $4.17.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.